COVER PAGE
COVER PAGE - shares | 6 Months Ended | |
Dec. 30, 2023 | Feb. 07, 2024 | |
Cover [Abstract] | ||
Document Type | 10-Q | |
Document Quarterly Report | true | |
Document Period End Date | Dec. 30, 2023 | |
Document Transition Report | false | |
Entity File Number | 0-11559 | |
Entity Registrant Name | KEY TRONIC CORPORATION | |
Entity Incorporation, State or Country Code | WA | |
Entity Tax Identification Number | 91-0849125 | |
Entity Address, Address Line One | N. 4424 Sullivan Road | |
Entity Address, City or Town | Spokane Valley | |
Entity Address, State or Province | WA | |
Entity Address, Postal Zip Code | 99216 | |
City Area Code | 509 | |
Local Phone Number | 928-8000 | |
Title of 12(b) Security | Common Stock, no par value | |
Trading Symbol | KTCC | |
Security Exchange Name | NASDAQ | |
Entity Current Reporting Status | Yes | |
Entity Interactive Data Current | Yes | |
Entity Filer Category | Non-accelerated Filer | |
Entity Small Business | true | |
Entity Emerging Growth Company | false | |
Entity Shell Company | false | |
Entity Common Stock, Shares Outstanding | 10,761,871 | |
Amendment Flag | false | |
Document Fiscal Year Focus | 2023 | |
Document Fiscal Period Focus | Q2 | |
Entity Central Index Key | 0000719733 | |
Current Fiscal Year End Date | --06-29 |
CONSOLIDATED BALANCE SHEETS
CONSOLIDATED BALANCE SHEETS - USD ($) $ in Thousands | Dec. 30, 2023 | Jul. 01, 2023 |
Current assets: | ||
Cash and cash equivalents | $ 2,953 | $ 3,603 |
Trade receivables, net of allowance for doubtful accounts of $72 and $23 | 134,892 | 150,600 |
Contract assets | 27,770 | 29,925 |
Inventories | 124,054 | 137,911 |
Other | 22,612 | 27,510 |
Total current assets | 312,281 | 349,549 |
Property, plant and equipment, net | 28,935 | 28,870 |
Operating lease right-of-use assets, net | 18,104 | 16,202 |
Other assets: | ||
Deferred income tax asset | 13,161 | 12,254 |
Other | 6,243 | 11,397 |
Total other assets | 19,404 | 23,651 |
Total assets | 378,724 | 418,272 |
Current liabilities: | ||
Accounts payable | 91,358 | 115,899 |
Accrued compensation and vacation | 5,677 | 13,351 |
Current portion of debt, net | 5,610 | 7,849 |
Other | 15,721 | 14,867 |
Total current liabilities | 118,366 | 151,966 |
Long-term liabilities: | ||
Term loans | 6,465 | 6,726 |
Revolving loan | 108,429 | 114,805 |
Operating lease liabilities | 12,380 | 10,317 |
Deferred income tax liability | 22 | 274 |
Other long-term obligations | 627 | 3,567 |
Total long-term liabilities | 127,923 | 135,689 |
Total liabilities | 246,289 | 287,655 |
Commitments and contingencies | ||
Shareholders’ equity: | ||
Common stock, no par value—shares authorized 25,000; issued and outstanding 10,762 and 10,762 shares, respectively | 47,839 | 47,728 |
Retained earnings | 84,405 | 82,986 |
Accumulated other comprehensive Income (loss) | 191 | (97) |
Total shareholders’ equity | 132,435 | 130,617 |
Total liabilities and shareholders’ equity | $ 378,724 | $ 418,272 |
CONSOLIDATED BALANCE SHEETS (Pa
CONSOLIDATED BALANCE SHEETS (Parenthetical) - USD ($) shares in Thousands, $ in Thousands | Dec. 30, 2023 | Jul. 01, 2023 |
Statement of Financial Position [Abstract] | ||
Trade receivables, allowance for doubtful accounts | $ 72 | $ 23 |
Common stock, shares authorized (in shares) | 25,000 | 25,000 |
Common stock, shares issued (in shares) | 10,762 | 10,762 |
Common stock, shares outstanding (in shares) | 10,762 | 10,762 |
CONSOLIDATED STATEMENTS OF INCO
CONSOLIDATED STATEMENTS OF INCOME - USD ($) shares in Thousands | 3 Months Ended | 6 Months Ended | ||
Dec. 30, 2023 | Dec. 31, 2022 | Dec. 30, 2023 | Dec. 31, 2022 | |
Income Statement [Abstract] | ||||
Net sales | $ 145,417,000 | $ 123,708,000 | $ 293,180,000 | $ 260,971,000 |
Cost of sales | 133,654,000 | 114,788,000 | 270,555,000 | 241,672,000 |
Gross profit | 11,763,000 | 8,920,000 | 22,625,000 | 19,299,000 |
Research, development and engineering expenses | 1,758,000 | 2,287,000 | 3,999,000 | 4,583,000 |
Selling, general and administrative expenses | 6,057,000 | 5,735,000 | 11,841,000 | 11,391,000 |
Gain on insurance proceeds, net of losses | 0 | (2,710,000) | (431,000) | (3,644,000) |
Total operating expenses | 7,815,000 | 5,312,000 | 15,409,000 | 12,330,000 |
Operating income | 3,948,000 | 3,608,000 | 7,216,000 | 6,969,000 |
Interest expense, net | 2,961,000 | 2,507,000 | 5,972,000 | 4,394,000 |
Income before income taxes | 987,000 | 1,101,000 | 1,244,000 | 2,575,000 |
Income tax provision (benefit) | (97,000) | 134,000 | (175,000) | 456,000 |
Net income | $ 1,084,000 | $ 967,000 | $ 1,419,000 | $ 2,119,000 |
Net income per share - Basic (in USD per share) | $ 0.10 | $ 0.09 | $ 0.13 | $ 0.20 |
Weighted average shares outstanding — Basic (in shares) | 10,762 | 10,762 | 10,762 | 10,762 |
Net income per share - Diluted (in USD per share) | $ 0.10 | $ 0.09 | $ 0.13 | $ 0.20 |
Weighted average shares outstanding — Diluted (in shares) | 10,889 | 10,832 | 10,889 | 10,832 |
CONSOLIDATED STATEMENTS OF COMP
CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME - USD ($) $ in Thousands | 3 Months Ended | 6 Months Ended | ||
Dec. 30, 2023 | Dec. 31, 2022 | Dec. 30, 2023 | Dec. 31, 2022 | |
Comprehensive income: | ||||
Net income | $ 1,084 | $ 967 | $ 1,419 | $ 2,119 |
Other comprehensive income (loss): | ||||
Unrealized gain (loss) on hedging instruments, net of tax | 230 | 59 | 288 | 212 |
Comprehensive income (loss) | $ 1,314 | $ 1,026 | $ 1,707 | $ 2,331 |
CONSOLIDATED STATEMENTS OF CO_2
CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (Parenthetical) - USD ($) $ in Millions | 3 Months Ended | 6 Months Ended | ||
Dec. 30, 2023 | Dec. 31, 2022 | Dec. 30, 2023 | Dec. 31, 2022 | |
Statement of Comprehensive Income [Abstract] | ||||
Net of tax expense (benefit) | $ (0.1) | $ 0 | $ (0.1) | $ 0 |
CONSOLIDATED STATEMENTS OF CASH
CONSOLIDATED STATEMENTS OF CASH FLOWS - USD ($) | 6 Months Ended | |
Dec. 30, 2023 | Dec. 31, 2022 | |
Operating activities: | ||
Net income | $ 1,419,000 | $ 2,119,000 |
Adjustments to reconcile net income to cash used in operating activities: | ||
Depreciation and amortization | 5,498,000 | 4,658,000 |
Amortization of interest rate swap | 97,000 | 211,000 |
Amortization of deferred loan costs | 137,000 | 51,000 |
Noncash lease expense | 2,928,000 | 3,128,000 |
Inventory write-down to net realizable value | 2,000 | 355,000 |
Provision for warranty | 138,000 | 266,000 |
Provision for doubtful accounts | 49,000 | 22,000 |
Gain on disposal of assets | (36,000) | (123,000) |
Gain on insurance proceeds, net of losses | (431,000) | (3,644,000) |
Share-based compensation expense | 111,000 | 102,000 |
Deferred income taxes | (1,213,000) | (120,000) |
Changes in operating assets and liabilities: | ||
Trade receivables | 15,708,000 | 1,564,000 |
Contract assets | 2,155,000 | (6,355,000) |
Inventories | 13,806,000 | (16,362,000) |
Other assets | 417,000 | (650,000) |
Accounts payable | (24,541,000) | 19,310,000 |
Accrued compensation and vacation | (7,675,000) | (4,023,000) |
Other liabilities | 511,000 | (10,540,000) |
Cash provided by (used in) operating activities | 9,080,000 | (10,031,000) |
Investing activities: | ||
Purchase of property and equipment | (2,609,000) | (3,859,000) |
Proceeds from insurance | 2,249,000 | 3,500,000 |
Cash used in investing activities | (360,000) | (359,000) |
Financing activities: | ||
Payment of financing costs | (625,000) | 0 |
Proceeds from issuance of long term debt | 1,161,000 | 0 |
Repayments of long term debt | (1,457,000) | (1,089,000) |
Borrowings under revolving credit agreement | 272,755,000 | 289,330,000 |
Repayments of revolving credit agreement | (278,643,000) | (276,778,000) |
Principal payments on finance leases | (2,561,000) | (1,970,000) |
Cash (used in) provided by financing activities | (9,370,000) | 9,493,000 |
Net decrease in cash and cash equivalents | (650,000) | (897,000) |
Cash and cash equivalents, beginning of period | 3,603,000 | 1,707,000 |
Cash and cash equivalents, end of period | 2,953,000 | 810,000 |
Supplemental cash flow information: | ||
Interest payments | 6,015,000 | 3,712,000 |
Income tax payments, net of refunds | 1,602,000 | 776,000 |
Recognition of operating lease liabilities and right-of-use assets | 3,575,000 | 5,049,000 |
Recognition of financing lease liabilities and right-of-use assets | $ 0 | $ 0 |
CONSOLIDATED STATEMENTS OF SHAR
CONSOLIDATED STATEMENTS OF SHAREHOLDER'S EQUITY - USD ($) shares in Thousands, $ in Thousands | Total | Common Stock | Retained Earnings | Accumulated Other Comprehensive Income (Loss) |
Beginning balances at Jul. 02, 2022 | $ 124,878 | $ 47,475 | $ 77,829 | $ (425) |
Beginning balances (in shares) at Jul. 02, 2022 | 10,762 | |||
Increase (Decrease) in Stockholders' Equity [Roll Forward] | ||||
Exercise of stock appreciation rights (in shares) | 0 | |||
Share-based compensation | $ 101 | |||
Exercise of stock options | 0 | |||
Net income | 2,119 | 2,119 | ||
Unrealized gain (loss) on hedging instruments, net of tax | 212 | 212 | ||
Ending balances at Dec. 31, 2022 | 127,311 | $ 47,576 | 79,948 | (213) |
Ending balances (in shares) at Dec. 31, 2022 | 10,762 | |||
Beginning balances at Oct. 01, 2022 | 126,223 | $ 47,514 | 78,981 | (272) |
Beginning balances (in shares) at Oct. 01, 2022 | 10,762 | |||
Increase (Decrease) in Stockholders' Equity [Roll Forward] | ||||
Exercise of stock appreciation rights (in shares) | 0 | |||
Share-based compensation | $ 62 | |||
Exercise of stock options | 0 | |||
Net income | 967 | 967 | ||
Unrealized gain (loss) on hedging instruments, net of tax | 59 | 59 | ||
Ending balances at Dec. 31, 2022 | 127,311 | $ 47,576 | 79,948 | (213) |
Ending balances (in shares) at Dec. 31, 2022 | 10,762 | |||
Beginning balances at Jul. 01, 2023 | $ 130,617 | $ 47,727 | 82,986 | (97) |
Beginning balances (in shares) at Jul. 01, 2023 | 10,762 | 10,762 | ||
Increase (Decrease) in Stockholders' Equity [Roll Forward] | ||||
Exercise of stock appreciation rights (in shares) | 0 | |||
Share-based compensation | $ 112 | |||
Exercise of stock options | 0 | |||
Net income | $ 1,419 | 1,419 | ||
Unrealized gain (loss) on hedging instruments, net of tax | 288 | 288 | ||
Ending balances at Dec. 30, 2023 | $ 132,435 | $ 47,839 | 84,405 | 191 |
Ending balances (in shares) at Dec. 30, 2023 | 10,762 | 10,762 | ||
Beginning balances at Sep. 30, 2023 | $ 131,069 | $ 47,786 | 83,321 | (39) |
Beginning balances (in shares) at Sep. 30, 2023 | 10,762 | |||
Increase (Decrease) in Stockholders' Equity [Roll Forward] | ||||
Exercise of stock appreciation rights (in shares) | 0 | |||
Share-based compensation | $ 53 | |||
Exercise of stock options | 0 | |||
Net income | 1,084 | 1,084 | ||
Unrealized gain (loss) on hedging instruments, net of tax | 230 | 230 | ||
Ending balances at Dec. 30, 2023 | $ 132,435 | $ 47,839 | $ 84,405 | $ 191 |
Ending balances (in shares) at Dec. 30, 2023 | 10,762 | 10,762 |
Basis of Presentation
Basis of Presentation | 6 Months Ended |
Dec. 30, 2023 | |
Organization, Consolidation and Presentation of Financial Statements [Abstract] | |
Basis of Presentation | Basis of Presentation The consolidated financial statements included herein have been prepared by Key Tronic Corporation and subsidiaries (the Company) pursuant to the rules and regulations of the Securities and Exchange Commission (SEC). Certain information and footnote disclosures normally included in our annual consolidated financial statements have been condensed or omitted. The year-end condensed consolidated balance sheet information was derived from audited financial statements, but does not include all disclosures required by accounting principles generally accepted in the United States of America. The financial statements reflect all normal and recurring adjustments which, in the opinion of management, are necessary for a fair presentation of the financial position, results of operations and cash flows for the interim periods presented. The preparation of financial statements in accordance with generally accepted accounting principles requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and the reported amounts of revenues and expenses during the reporting period. The results of operations for the periods presented are not necessarily indicative of the results to be expected for the full year. The accompanying unaudited condensed consolidated financial statements should be read in conjunction with the financial statements and notes included in the Company’s Annual Report on Form 10-K for the fiscal year ended July 1, 2023. The Company’s reporting period is a 52/53 week fiscal year ending on the Saturday closest to June 30. The three month and six month periods ended December 30, 2023 and December 31, 2022, were both 13 week and 26 week periods. Fiscal year 2024 will end on June 29, 2024, which is a 52 week year. Fiscal year 2023 which ended on July 1, 2023, was also a 52 week year. Management’s Assessment of Liquidity Historically, we have financed operations and met our capital expenditure requirements primarily through cash flows provided by operations and borrowings under our credit facilities. We generated operating and net income of $3.9 million and $1.1 million respectively, during the 3-month period ended December 30, 2023, and have positive working capital of $193.9 million as of December 30, 2023. Due to the timing between the procurement of raw materials, production cycle and payment from our customers, we have relied on borrowings on our credit facilities and cash from operations to fund operations of the Company. Based on current projections, we anticipate generating cash from operations as revenue is expected to remain flat during the third quarter of fiscal year 2024 and decreasing working capital requirements as existing backlog is manufactured and shipped. As of December 30, 2023, approximately $14.4 million was available under the asset-based revolving credit facility with Bank of America, and an additional $2.0 million was available under the asset-based line of credit with Banorte Financial Group. We are also in discussions with multiple financial institutions to extend the borrowing capacity on our credit facility. If we are unable to meet projected operating results or extend our borrowing capacity, we may need to delay the purchase of raw materials or require our customers to fund inventory raw material costs ahead of production. Other options to increase our liquidity include factoring receivables or leveraging foreign owned assets for additional borrowing capacity. We believe that projected cash from operations, funds available under our asset-based revolving credit facility and additional financing options will be sufficient to meet our working and fixed capital requirements for at least the next 12 months. Certain Significant Risks and Uncertainties Related to Outbreak of Coronavirus Disease 2019 (“COVID-19”) Due to the COVID-19 pandemic, the Company has seen extreme shifts in demand from its customer base, and shifts in supply chain and logistics risks. The possibility of future temporary closures, as well as adverse fluctuations in customer demand, freight and expedite costs, precautionary safety expenses and labor shortages, collectability of accounts, and future supply chain disruptions during the rapidly changing COVID-19 environment can materially impact operating results. Additionally, continued adverse macroeconomic conditions and significant currency exchange fluctuations can also materially impact operating results. |
Significant Accounting Policies
Significant Accounting Policies | 6 Months Ended |
Dec. 30, 2023 | |
Accounting Policies [Abstract] | |
Significant Accounting Policies | Significant Accounting Policies Reclassifications Certain prior period reclassifications were made to conform with the current period presentation. These reclassifications had no effect on reported income, comprehensive income, cash flows, total assets, or shareholders' equity as previously reported. Earnings Per Common Share Basic earnings per common share (EPS) is computed by dividing net income (loss) by the weighted average number of common shares outstanding during the period. Diluted EPS is computed by dividing net income (loss) by the combination of other potentially dilutive weighted average common shares and the weighted average number of common shares outstanding during the period using the treasury stock method. The computation assumes the proceeds from the exercise of equity awards were used to repurchase common shares at the average market price during the period. The computation of diluted EPS does not assume conversion, exercise, or contingent issuance of common stock equivalent shares that would have an anti-dilutive effect on EPS. Derivative Instruments and Hedging Activities The Company has entered into foreign currency forward contracts which are accounted for as cash flow hedges in accordance with ASC 815, Derivatives and Hedging. The effective portion of the gain or loss on the derivative is reported as a component of accumulated other comprehensive income (AOCI) and is reclassified into earnings in the same period in which the underlying hedged transaction affects earnings. The derivative’s effectiveness represents the change in fair value of the hedge that offsets the change in fair value of the hedged item. The Company uses derivatives to manage the variability of foreign currency fluctuations of expenses in our Mexico facilities. The foreign currency forward contracts have terms that are matched to the underlying transactions being hedged. As a result, these transactions fully offset the hedged risk and no ineffectiveness has been recorded. The Company’s foreign currency forward contracts potentially expose the Company to credit risk to the extent the counterparty may be unable to meet the terms of the agreement. The Company minimizes such risk by utilizing a counterparty with a strong credit rating. The Company’s counterparty to the foreign currency forward contracts is a major banking institution. This institution does not require collateral for the contracts, and the Company believes that the risk of the counterparty failing to meet their contractual obligations is remote. The Company does not enter into derivative instruments for trading or speculative purposes. Income Taxes We compute our interim income tax provision through the use of an estimated annual effective tax rate (ETR) applied to year-to-date operating results and specific events that are discretely recognized as they occur. In determining the estimated annual ETR, we analyze various factors, including projections of our annual earnings, taxing jurisdictions in which the earnings will be generated, the impact of state and local income taxes, our ability to use tax credits and available tax planning alternatives. Discrete items, including the effect of changes in tax laws, tax rates, and certain circumstances with respect to valuation allowances or other unusual or non-recurring tax adjustments, are reflected in the period in which they occur as an addition to, or reduction from, the income tax provision, rather than included in the estimated annual ETR. Income taxes are accounted for under the asset and liability method. Deferred tax assets and liabilities are recognized for the estimated future tax consequences and benefits attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases, as well as tax credit and net operating loss carryforwards. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which temporary differences and carryforwards are expected to be recovered or settled. The effect on deferred tax assets and liabilities for a change in tax rates is recognized in the period that includes the enactment date. Valuation allowances are established when necessary to reduce deferred tax assets to the amount that is more likely than not to be realized. We utilize a two-step approach to recognizing and measuring uncertain tax positions. The first step is to evaluate the tax position for recognition by determining if the weight of available evidence indicates it is more likely than not that the position will be sustained on audit, including resolution of related appeals or litigation processes, if any. The second step is to measure the tax benefit as the largest amount which is more than 50% likely of being realized upon ultimate settlement. We consider many factors when evaluating and estimating our tax positions and tax benefits, which may require periodic adjustments based on new assessments and changes in estimates and which may not accurately forecast actual outcomes. Our policy is to recognize interest and penalties related to the underpayment of income taxes as a component of income tax expense. The tax years 2001 through the present remain open to examination by the major U.S. taxing jurisdictions to which we are subject. Refer to Note 5 for further discussions. Recently Issued Accounting Standards On Dec. 14, 2023, the Financial Accounting Standards Board (FASB) issued ASU 2023-09, Income Taxes (Topic 740): Improvements to Income Tax Disclosures. The ASU requires entities to disclose more detailed information relating to their reconciliation of statutory tax rate to effective tax rate, income taxes paid by jurisdiction, pretax income (or loss) from continuing operations, and income tax expense (or benefit). The ASU applies to the Company’s annual reporting period beginning in fiscal year 2026. The Company does not anticipate early adoption of the new disclosure standards. In September 2022, the Financial Accounting Standards Board issued Accounting Standards Update ("ASU") No. 2022-04, Liabilities—Supplier Finance Programs (Subtopic 405-50). This standard requires disclosure of the key terms of outstanding supplier finance programs and a roll forward of the related obligations. The new standard does not affect the recognition, measurement or financial statement presentation of supplier finance program obligations. The ASU became effective for the Company July 2, 2023, except for the roll forward requirement, which becomes effective July 2, 2024. This ASU, except for the roll forward requirement, was adopted retrospectively as of July 2, 2023 and did not have a material impact on our consolidated financial statements. In October 2021, the Financial Accounting Standards Board (FASB) issued Accounting Standards Update (ASU) 2021-08 amending Business Combination: (Topic 805), which was necessary due to 2014-09, Revenue from Contracts with Customers (Topic 606). The FASB issued this Update to improve the accounting for acquired revenue contracts with customers in a business combination by addressing diversity in practice and inconsistency related to (1) recognition of an acquired contract liability and (2) payment terms and their effect on subsequent revenue recognized by the acquirer. The Company adopted this amendment as of the effective date of July 2, 2023. These amendments are to be applied prospectively to business combinations occurring on or after the effective date of the amendments. The Company plans to apply the practical expedients as needed for any future acquisitions. The practical expedients cover contracts that were modified prior to acquisition date as well as determining which date an acquirer would have to determine the standalone selling price of each performance obligation in an acquired contract. This ASU did not have a material impact on our consolidated financial statements. In March of 2020, the FASB issued ASU 2020-03, Codification Improvements to Financial Instruments, which clarifies specific issues raised by stakeholders. Specifically, the ASU clarifies the following: 1) that all entities are required to provide the fair value option disclosures in ASC 825, Financial Instruments 2) clarifies that the portfolio exception in ASC 820, Fair Value Measurement, applies to nonfinancial items accounted for as derivatives under ASC 815, Derivatives and Hedging; 3) clarifies that for purposes of measuring expected credit losses on a net investment in a lease in accordance with ASC 326, Financial Instruments - Credit Losses, the lease term determined in accordance with ASC 842, Leases, should be used as the contractual term; 4) clarifies that when an entity regains control of financial assets sold, it should recognize an allowance for credit losses in accordance with ASC 326; and 5) aligns the disclosure requirements for debt securities in ASC 320, Investments - Debt Securities, with the corresponding requirements for depository and lending institutions in ASC 942, Financial Services - Depository and Lending. The amendments in the ASU have various effective dates and transition requirements which are dependent on timing of adoption of ASU 2016-13. The Company adopted this amendment as of the effective date of July 2, 2023. This ASU did not have a material impact on our consolidated financial statements. In June 2016, the FASB issued ASU 2016-13 “Financial Instruments - Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments” and also issued subsequent amendments to the initial guidance: ASU 2018-19, ASU 2019-04 and ASU 2019-05, which replaces the existing incurred loss impairment model with an expected credit loss model and requires a financial asset measured at amortized cost to be presented at the net amount expected to be collected. The guidance is effective for the Company beginning in the first quarter of fiscal year 2024 with early adoption permitted. The Company adopted this amendment as of the effective date of July 2, 2023. This ASU did not have a material impact on our consolidated financial statements. |
Inventories
Inventories | 6 Months Ended |
Dec. 30, 2023 | |
Inventory Disclosure [Abstract] | |
Inventories | Inventories |
Long-Term Debt
Long-Term Debt | 6 Months Ended |
Dec. 30, 2023 | |
Debt Disclosure [Abstract] | |
Long-Term Debt | Long-Term Debt On August 14, 2020, the Company entered into a loan agreement with Bank of America. The Loan Agreement replaces the Company’s prior amended and restated credit agreement, as amended, with Wells Fargo Bank. The Loan Agreement provides for a five-year asset-based senior secured revolving credit facility of up to $93 million, maturing on August 14, 2025. On September 3, 2021, the Company entered into an amendment to the Company’s current loan agreement with Bank of America. The amendment increases the Company’s current credit facility to $120 million, subject to the Company’s borrowing base, maturing on September 3, 2026. As of December 30, 2023, the Company had an outstanding balance under the asset-based revolving credit facility of $105.6 million, $0.3 million in outstanding letters of credit and $14.4 million available for future borrowings. On August 26, 2022, the company entered into a third amendment to the loan agreement with Bank of America. The amendment removed the cash flow leverage ratio covenant and increased the interest rate by 25 basis points. As of July 1, 2023, the Company had an outstanding balance under the credit facility with Bank of America of $115.4 million, $0.3 million in outstanding letters of credit and $4.6 million available for future borrowings. Generally, the interest rate applicable to loans under the Bank of America loan agreement will be, at the Company’s option: (i)(A) the base rate which is the highest of (1) the prime rate for the applicable day (as such rate is determined from time to time by the Bank), (2) the federal funds rate for the applicable day plus 0.50%, and (3) LIBOR for a 30-day interest period as of the applicable day plus 1.00% (provided that in no event shall the base rate be less than zero), plus the applicable interest margin for base rate loans; and (B) LIBOR rate for an applicable interest period (provided that in no event shall the LIBOR rate be less than 0.50%), plus the applicable interest margin for LIBOR rate loans. Depending on average daily excess borrowing availability over applicable periods under the Credit Facility, applicable interest margins on: (x) base rate loans will be 1.25-1.75%; and (y) LIBOR rate loans will be 2.25-2.75%, resetting on a quarterly basis beginning in early 2021. If there is an event of default under the loan agreement, all loans and other obligations will bear interest at a rate of an additional 2.00% on the otherwise applicable interest rates. In addition to interest charges, the Company is required to pay a fee of 0.25% per annum on the unused portion of the Credit Facility, monthly in arrears. Under the new loan agreement with Bank of America, the asset-based revolving credit facility bears interest at LIBOR plus 2.5%, as elected by the Company. On December 11, 2023, the Company entered into a loan agreement in Mexican peso with Banorte Financial Group. The agreement provides for three-year asset-based secured line of credit up to $5.9 million, subject to the Company’s borrowing base, maturing on December 11, 2026. The credit facility bears interest at Itercambaria de Equilibrio Interest Rate plus 2.75%. As of December 30, 2023, the Company had an outstanding balance under the asset-based revolving credit facility of $3.9 million and $2.0 million available for future borrowings. On September 19, 2023, the Company entered into another $1.1 million equipment financing agreement with Ameris Bank dba Balboa Capital ("Balboa Capital"). Combining with agreements entered in the third quarter of fiscal year 2023, the total $5.5 million relates to the Company’s existing manufacturing equipment that bears an interest rate range of 6% - 8% and matures in the first quarter of fiscal 2030. Under these agreements, equal monthly payments of $94,000 commenced in the second quarter of fiscal year 2024 and will continue through the maturity of the equipment financing facility in the first quarter of fiscal 2030. The Company had an outstanding balance $4.9 million as of December 30, 2023. On August 14, 2020, the Company also entered into a $5.0 million equipment financing facility relating to the Company’s existing U.S. manufacturing equipment that bears interest at 4.85% and matures on August 14, 2025. Under this loan agreement, equal monthly payments of approximately $94,000 commenced on September 14, 2020 and will continue through the maturity of the equipment financing facility on August 14, 2025. As of December 30, 2023, the Company had an outstanding balance of $1.8 million. As of July 1, 2023, the Company had an outstanding balance of $2.3 million under the Bank of America equipment term loan agreement. On November 24, 2020, the Company entered into a $6.0 million equipment financing facility related to the Company’s existing manufacturing equipment that bears interest at 5.52% and matures on April 24, 2026. Under this loan agreement, equal monthly payments of $100,000 commenced on May 24, 2021 and will continue through the maturity of the equipment financing facility on April 24, 2026. As of December 30, 2023, the Company had an outstanding balance of $2.8 million. As of July 1, 2023, the Company had an outstanding balance of $3.4 million. The interest rates on outstanding debt as of December 30, 2023 range from 4.85% - 14.25% compared to 4.85% - 8.22% as of July 1, 2023. Debt maturities as of December 30, 2023 for the next five years and thereafter are as follows (in thousands): Fiscal Years Ending Amount 2024 (1) $ 1,520 2025 3,123 2026 2,081 2027 110,468 2028 1,032 2029 - Thereafter 816 Total debt $ 119,040 Unamortized debt issuance costs (1,078) Long-term debt, net of debt issuance costs $ 117,962 (1) Represents scheduled payments for the remaining six-month period ending June 29, 2024. The Company must comply with certain financial covenants, including a fixed charge coverage ratio. The Company was in compliance with all financial covenants as of December 30, 2023. |
Income Taxes
Income Taxes | 6 Months Ended |
Dec. 30, 2023 | |
Income Tax Disclosure [Abstract] | |
Income Taxes | Income Taxes The Company expects to repatriate a portion of its foreign earnings based on increased net sales growth driving additional capital requirements domestically, cash requirements for potential acquisitions and to implement certain tax strategies. The Company currently expects to repatriate approximately $7.8 million of foreign earnings in the future. All other unremitted foreign earnings are expected to remain permanently reinvested for planned fixed assets purchases and improvements in foreign locations. Repatriations of cash will generally be tax-free in the U.S. However, withholding taxes in China may still apply to any such future repatriations. Management has not changed its indefinite investment assertions with regard to the portion of accumulated earnings and profits in China that may be repatriated in the future. Accordingly, management estimates that future repatriations of cash from China may result in approximately $0.8 million of withholding tax. We do not anticipate there would be any offsetting foreign tax credits in the U.S. and as such, this potential liability is a direct cost associated with actual repatriations. Withholding taxes would not apply to future repatriations from Mexico or Vietnam. The Company has available approximately $10.0 million of gross federal research and development tax credits as of December 30, 2023. ASC 740 requires the Company to recognize in its financial statements uncertainties in tax positions taken that may not be sustained upon examination by the taxing authorities. Accordingly, as of December 30, 2023, the Company has recorded $3.1 million of unrecognized tax benefits associated with these federal tax credits, resulting in a net deferred tax benefit of approximately $6.9 million. The Company evaluated tax law changes and regulatory guidance issued through the prior fiscal year. Such changes and regulations include guidance relating to foreign tax credits and consolidated NOL carryback claims. The Company evaluated the ongoing impact of these law and regulatory changes, and determined that they did not have a material impact on its provision for income taxes. On August 16, 2022, the Inflation Reduction Act of 2022 was signed into law. The Inflation Reduction Act of 2022 includes a new book minimum tax on certain large corporations and an excise tax on corporate stock buybacks, among other provisions. The Company has evaluated the impacts of this Act, and at this time the Company does not believe they will have a material impact on our consolidated financial position, results of operations, or cash flows. |
Earnings Per Share
Earnings Per Share | 6 Months Ended |
Dec. 30, 2023 | |
Earnings Per Share [Abstract] | |
Earnings Per Share | Earnings Per Share The following table presents a reconciliation of the denominator in the basic and diluted EPS calculation and the number of antidilutive common share awards that were not included in the diluted earnings per share calculation. These antidilutive securities occur when equity awards outstanding have an option price greater than the average market price for the period. Three Months Ended (in thousands, except share and per share information) December 30, 2023 December 31, 2022 Net income $ 1,084 $ 967 Weighted average shares outstanding—basic 10,762 10,762 Effect of dilutive common stock awards 127 70 Weighted average shares outstanding—diluted 10,889 10,832 Net income per share—basic $ 0.10 $ 0.09 Net income per share—diluted $ 0.10 $ 0.09 Antidilutive SARs not included in diluted earnings per share 525 904 Six Months Ended (in thousands, except per share information) December 30, 2023 December 31, 2022 Net income $ 1,419 $ 2,119 Weighted average shares outstanding—basic 10,762 10,762 Effect of dilutive common stock awards 127 70 Weighted average shares outstanding—diluted 10,889 10,832 Net income per share—basic $ 0.13 $ 0.20 Net income per share—diluted $ 0.13 $ 0.20 Antidilutive SARs not included in diluted earnings per share 525 904 |
Share-based Compensation
Share-based Compensation | 6 Months Ended |
Dec. 30, 2023 | |
Share-Based Payment Arrangement [Abstract] | |
Share-based Compensation | Share-based Compensation The Company’s incentive plan provides for equity and liability awards to employees and non-employee directors in the form of stock options, stock appreciation rights (SARs), restricted stock, restricted stock units, stock awards, stock units, performance shares, performance units, and other stock-based or cash-based awards. Compensation cost is recognized on a straight-line basis over the requisite employee service period, which is generally the vesting period, and is recorded as employee compensation expense in cost of goods sold, research, development and engineering, and selling, general and administrative expenses. Share-based compensation is recognized only for those awards that are expected to vest, with forfeitures estimated at the date of grant based on historical experience and future expectations. In addition to service conditions, SARs contain a performance condition. The additional performance condition is based upon the achievement of Return on Invested Capital (ROIC) goals relative to a peer group. All awards with performance conditions are evaluated quarterly to determine the likelihood that performance metrics will be achieved during the performance period. These awards are charged to compensation expense over the requisite service period based on the number of shares expected to vest. The SARs cliff vest after a three-year period from date of grant and expire five years from date of grant. The grant date fair value for the awards granted below were estimated using the Black Scholes option valuation method: July 29, 2022 SARs Granted 145,000 Strike Price $ 5.10 Fair Value $ 2.09 Total share-based compensation expense recognized during the three months ended December 30, 2023 and December 31, 2022 was approximately $52,297 and $62,000, respectively. Total share-based compensation expense recognized during the six months ended December 30, 2023 and December 31, 2022 was approximately $111,239 and $102,000, respectively. |
Commitments and Contingencies
Commitments and Contingencies | 6 Months Ended |
Dec. 30, 2023 | |
Commitments and Contingencies Disclosure [Abstract] | |
Commitments and Contingencies | Commitments and Contingencies Litigation and Other Matters The Company is party to certain lawsuits or claims in the ordinary course of business. The Company does not believe that these proceedings, individually or in the aggregate, will have a material adverse effect on the financial position, results of operations or cash flow of the Company. Warranties The Company provides warranties on certain product sales. Allowances for estimated warranty costs are recorded during the period of sale. The determination of such allowances requires the Company to make estimates of product return rates and expected costs to repair or to replace the products under warranty. If actual return rates and/or repair and replacement costs differ significantly from management’s estimates, adjustments to recognize additional cost of sales may be required in future periods. The Company’s warranty reserve was approximately $107,000 as of December 30, 2023 and $29,000 as of July 1, 2023, respectively. Gain from Insurance Recoveries, Net of Losses Gain from insurance recoveries, net of losses, relate to losses incurred from storm damage to the Company’s Arkansas facility on July 29, 2022, as the result of a lightning strike. During the six months ended December 30, 2023, the Company recorded a gain from insurance recoveries, net of losses, of $0.4 million. The Company did not record a gain during the three months ended December 30, 2023. |
Derivative Financial Instrument
Derivative Financial Instruments | 6 Months Ended |
Dec. 30, 2023 | |
Derivative Instruments and Hedging Activities Disclosure [Abstract] | |
Derivative Financial Instruments | Derivative Financial Instruments As of December 30, 2023, the Company had outstanding foreign currency forward contracts with a total notional amount of $3.4 million. The maturity dates for these contracts extend through March 2024. For the three months ended December 30, 2023, the Company entered into $6.5 million of foreign currency forward contracts and settled $3.2 million of contracts. During the same period of the previous year, the Company did not enter or settle any foreign currency forward contracts. For the six months ended December 30, 2023, the Company entered into $6.5 million of foreign currency forward contracts and settled $3.2 million of contracts. During the same period of the previous year, the Company did not enter or settle any foreign currency forward contracts. As of December 30, 2023, the aggregate notional amount of the Company’s outstanding foreign currency contracts along with their unrealized gain (losses) are expected to mature as summarized below (in thousands): Quarter Ending Notional Contracts in MXN Notional Contracts in USD Estimated Fair Value March 30, 2024 $ 61,775 $ 3,369 $ 247 On November 6, 2019, the Company entered into an interest rate swap contract with an effective date of November 6, 2019 and a termination date of September 30, 2022, related to the borrowings outstanding under the term loan with Wells Fargo Bank. This interest rate swap contract was terminated on August 14, 2020 when the Company entered into a loan and security agreement with Bank of America. On the date of termination this interest rate swap was in a liability position of $148,400, which has been amortized to interest expense over the original term of the swap. On November 6, 2019, the Company entered into an interest rate swap contract with an effective date of November 6, 2019 and a termination date of November 1, 2023, related to the borrowings outstanding under the line of credit with Wells Fargo Bank. This interest rate swap contract was terminated on August 14, 2020 when the Company entered into a loan and security agreement with Bank of America. On the date of termination this interest rate swap was in a liability position of $776,500, which will be amortized to interest expense over the original term of the swap. The following tables summarize the gain (loss) on derivative instruments, net of tax, on the Consolidated Statements of Income for the three months ended December 30, 2023 and December 31, 2022, respectively (in thousands): Derivatives Designated as Hedging Instruments Classification of Gain (Loss) Reclassified from Accumulated OCI into Income (Effective Portion) AOCI Balance Effective Effective Portion AOCI Balance Forward contracts Cost of sales $ — $ 263 $ (72) $ 191 Interest rate swap Interest expense (39) — 39 — Total $ (39) $ 263 $ (33) $ 191 Derivatives Designated as Hedging Instruments Classification of Gain (Loss) Reclassified from Accumulated OCI into Income (Effective Portion) AOCI Balance Effective Effective Portion AOCI Balance Forward contracts Cost of sales $ — $ — $ — $ — Interest rate swap Interest expense (272) — 59 (213) Total $ (272) $ — $ 59 $ (213) The following tables summarize the gain (loss) on derivative instruments, net of tax, on the Consolidated Statements of Income for the six months ended December 30, 2023 and December 31, 2022, respectively (in thousands): Derivatives Designated as Hedging Instruments Classification of Gain (Loss) Reclassified from Accumulated OCI into Income (Effective Portion) AOCI Balance Effective Effective Portion AOCI Balance Forward contracts Cost of sales $ — $ 263 $ (72) $ 191 Interest rate swap Interest expense (97) — 97 — Total $ (97) $ 263 $ 25 $ 191 Derivatives Designated as Hedging Instruments Classification of Gain (Loss) Reclassified from Accumulated OCI into Income (Effective Portion) AOCI Balance Effective Effective Portion AOCI Balance Forward contracts Cost of sales $ (79) $ — $ 79 $ — Interest rate swap Interest expense (346) — 133 (213) Total $ (425) $ — $ 212 $ (213) As of December 30, 2023, the net amount of unrealized gain expected to be reclassified into earnings within the next 3 months is approximately $0.2 million. The Company does not have any foreign exchange contracts with credit-risk-related contingent features. The Company is subject to the risk of fluctuating interest rates from our line of credit and foreign currency risk resulting from our China operations. The Company does not currently manage these risk exposures by using derivative instruments. |
Revenue
Revenue | 6 Months Ended |
Dec. 30, 2023 | |
Revenue from Contract with Customer [Abstract] | |
Revenue | Revenue Revenue Recognition The Company specializes in services ranging from product manufacturing to engineering and tooling services. The first step in its process for revenue recognition is to identify the contract with a customer. A contract is defined as an agreement between two or more parties that creates enforceable rights and obligations. A contract can be written, oral, or implied. The Company generally enters into manufacturing service agreements (“MSA”) with its customers that outline the terms of the business relationship between the customer and the Company. This includes matters such as warranty, indemnification, transfer of title and risk of loss, liability for excess and obsolete inventory, pricing, payment terms, etc. The Company will also bid on a program-by-program basis for customers in which an executed MSA may not be in place. In these instances, as well as when we have an MSA in place, we receive customer purchase orders for specific quantities and timing of products. As a result, the Company considers its contract with a customer to be the combination of the MSA and the purchase order. The transaction price is fixed and set forth in each purchase order. In the Company's normal course of business, there are no variable pricing components, or material amounts refunded to customers in the form of refunds or rebates. The Company assesses whether control of the product or services promised under the contract is transferred to the customer at a point in time (shipment) or over time (as we manufacture the product). The Company is first required to evaluate whether its contracts meet the criteria for 'over-time' or 'point-in-time' recognition. The Company has determined that for the majority of its contracts the Company is manufacturing products for which there is no alternative use due to the unique nature of the customer-specific product, IP and other contract restrictions. The Company has an enforceable right to payment including a reasonable profit for performance completed to date with respect to these contracts. As a result, revenue is recognized under these contracts 'over-time' based on the input cost-to-cost method as it better depicts the transfer of control. This input method is based on the ratio of costs incurred to date as compared to the total estimated costs at completion of the performance obligation. For all other contracts that do not meet these criteria, such as manufacturing contracts for which the terms do not provide an enforceable right to payment for performance completed to date, the Company recognizes revenue when it has transferred control of the related manufactured products which generally occurs upon shipment to the customer. Revenue from engineering services is recognized over time as the services are performed. The Company’s sales arrangements do not contain any significant financing component for its customers. The Company generally provides a warranty for workmanship on its manufacturing contracts. Although we offer warranties on our products, our warranties are considered to be assurance-type in nature and do not cover anything beyond ensuring that the product is functioning as intended. Based on the guidance in ASC 606, assurance-type warranties do not represent separate performance obligations; therefore, the primary performance obligation in the majority of our contracts is the delivery of a specific good through the purchase order submitted by our customer. The Company elected not to disclose information about remaining performance obligations as they are part of contracts that that have expected durations of one year or less. The Company has elected to expense costs to obtain contracts as incurred as these costs are immaterial to the financial statements. During the first six months of fiscal year 2024, no revenues were recognized from performance obligations satisfied or partially satisfied in previous periods. Contract Balances A contract asset is recognized when the Company has recognized revenue, but has not issued an invoice for payment. Contract assets are classified separately on the condensed consolidated balance sheet and transferred to receivables when the right to payment becomes unconditional. The following table summarizes the activity in the Company’s contract assets during the six months ended December 30, 2023 (in thousands): Contract Assets Beginning balance, July 1, 2023 29,925 Revenue recognized 254,185 Amounts collected or invoiced (256,340) Ending balance, December 30, 2023 $ 27,770 Disaggregation of Revenue The following table presents the Company’s revenue disaggregated for the three and six months ended December 30, 2023 and December 31, 2022 (in thousands): Revenue Recognition Three Months Ended Six Months Ended December 30, 2023 December 31, 2022 December 30, 2023 December 31, 2022 Over-Time $ 124,205 $ 119,649 $ 254,185 $ 254,207 Point-in-Time 21,212 4,059 38,995 6,764 Total $ 145,417 $ 123,708 $ 293,180 $ 260,971 |
Leases
Leases | 6 Months Ended |
Dec. 30, 2023 | |
Leases [Abstract] | |
Leases | Leases The Company has several commitments under operating and financing leases for warehouses, manufacturing facilities, office buildings, and equipment with initial terms that expire at various dates during the next 1 year to 10 years. The Company has some leases that include an extension clause. Management has considered the likelihood of exercising each extension option included and estimated the duration of the extension option, for those leases management determined to be reasonably certain, in calculating the lease term for measurement of the right of use asset and liability. For operating leases, management assumed a discount rate of 4.28%. The weighted average discount rate is disclosed in the tables below. The components of lease cost for the three months and six months ended December 30, 2023 and were (in thousands): Three Months Ended Six Months Ended December 30, 2023 December 31, 2022 December 30, 2023 December 31, 2022 Lease cost Classification Operating lease cost Cost of sales $ 1,223 $ 2,441 $ 2,350 $ 3,775 Operating lease cost Selling, general and administrative expenses $ 183 $ 367 $ 367 $ 551 Financing lease cost Cost of sales $ 1,186 $ 1,859 $ 2,465 $ 2,759 Financing lease cost Selling, general and administrative expenses $ 49 $ 77 $ 104 $ 115 Total lease cost $ 2,641 $ 4,744 $ 5,286 $ 7,200 Fixed lease cost $ 1,336 $ 4,435 $ 2,434 $ 6,656 Short-term lease cost $ 1,305 $ 309 $ 2,852 $ 544 Total lease cost $ 2,641 $ 4,744 $ 5,286 $ 7,200 Amounts reported in the Consolidated Balance Sheet as of December 30, 2023 were (in thousands, except weighted average lease term and discount rate): December 30, 2023 July 1, 2023 Operating Leases: Operating lease right of use assets $ 18,104 $ 16,202 Operating lease liabilities (1) $ 18,104 $ 16,202 Weighted-average remaining lease term (in years) Operating leases 4.44 4.55 Weighted-average discount rate Operating leases 4.28% 4.00% Financing Leases (2) : Financing lease right of use assets $ 4,610 $ 9,718 Financing lease liabilities $ 3,170 $ 8,278 Weighted-average remaining lease term (in years) Financing leases 1.23 1.89 Weighted-average discount rate Financing leases 10.88% 9.96% (1) The current portion of the total operating lease liabilities of $5.7 million is classified under Other Current Liabilities , resulting in $12.4 million classified under Operating Lease Liabilities in the Long-term Liabilities section of the condensed consolidated balance sheet. (2) The total finance lease right of use assets of $4.6 million is classified under Other Long-term Assets The current portion of the total finance lease liabilities of $2.5 million is classified under Current portion of debt, net resulting in $0.6 million classified in Other Long-term Liabilities section of the condensed consolidated balance sheet. Future lease payments under non-cancellable leases as of December 30, 2023 are as follows (in thousands): Fiscal Years Ending Operating Leases Finance Leases 2024 (1) $ 3,034 $ 1,112 2025 5,080 1,909 2026 4,147 501 2027 3,238 — 2028 2,281 — Thereafter 1,873 — Total undiscounted lease payments 19,653 3,522 Less: present value discount (1,549) (352) Total lease liabilities $ 18,104 $ 3,170 |
Leases | Leases The Company has several commitments under operating and financing leases for warehouses, manufacturing facilities, office buildings, and equipment with initial terms that expire at various dates during the next 1 year to 10 years. The Company has some leases that include an extension clause. Management has considered the likelihood of exercising each extension option included and estimated the duration of the extension option, for those leases management determined to be reasonably certain, in calculating the lease term for measurement of the right of use asset and liability. For operating leases, management assumed a discount rate of 4.28%. The weighted average discount rate is disclosed in the tables below. The components of lease cost for the three months and six months ended December 30, 2023 and were (in thousands): Three Months Ended Six Months Ended December 30, 2023 December 31, 2022 December 30, 2023 December 31, 2022 Lease cost Classification Operating lease cost Cost of sales $ 1,223 $ 2,441 $ 2,350 $ 3,775 Operating lease cost Selling, general and administrative expenses $ 183 $ 367 $ 367 $ 551 Financing lease cost Cost of sales $ 1,186 $ 1,859 $ 2,465 $ 2,759 Financing lease cost Selling, general and administrative expenses $ 49 $ 77 $ 104 $ 115 Total lease cost $ 2,641 $ 4,744 $ 5,286 $ 7,200 Fixed lease cost $ 1,336 $ 4,435 $ 2,434 $ 6,656 Short-term lease cost $ 1,305 $ 309 $ 2,852 $ 544 Total lease cost $ 2,641 $ 4,744 $ 5,286 $ 7,200 Amounts reported in the Consolidated Balance Sheet as of December 30, 2023 were (in thousands, except weighted average lease term and discount rate): December 30, 2023 July 1, 2023 Operating Leases: Operating lease right of use assets $ 18,104 $ 16,202 Operating lease liabilities (1) $ 18,104 $ 16,202 Weighted-average remaining lease term (in years) Operating leases 4.44 4.55 Weighted-average discount rate Operating leases 4.28% 4.00% Financing Leases (2) : Financing lease right of use assets $ 4,610 $ 9,718 Financing lease liabilities $ 3,170 $ 8,278 Weighted-average remaining lease term (in years) Financing leases 1.23 1.89 Weighted-average discount rate Financing leases 10.88% 9.96% (1) The current portion of the total operating lease liabilities of $5.7 million is classified under Other Current Liabilities , resulting in $12.4 million classified under Operating Lease Liabilities in the Long-term Liabilities section of the condensed consolidated balance sheet. (2) The total finance lease right of use assets of $4.6 million is classified under Other Long-term Assets The current portion of the total finance lease liabilities of $2.5 million is classified under Current portion of debt, net resulting in $0.6 million classified in Other Long-term Liabilities section of the condensed consolidated balance sheet. Future lease payments under non-cancellable leases as of December 30, 2023 are as follows (in thousands): Fiscal Years Ending Operating Leases Finance Leases 2024 (1) $ 3,034 $ 1,112 2025 5,080 1,909 2026 4,147 501 2027 3,238 — 2028 2,281 — Thereafter 1,873 — Total undiscounted lease payments 19,653 3,522 Less: present value discount (1,549) (352) Total lease liabilities $ 18,104 $ 3,170 |
Pay vs Performance Disclosure
Pay vs Performance Disclosure - USD ($) $ in Thousands | 3 Months Ended | 6 Months Ended | ||
Dec. 30, 2023 | Dec. 31, 2022 | Dec. 30, 2023 | Dec. 31, 2022 | |
Pay vs Performance Disclosure | ||||
Net income | $ 1,084 | $ 967 | $ 1,419 | $ 2,119 |
Insider Trading Arrangements
Insider Trading Arrangements | 3 Months Ended |
Dec. 30, 2023 | |
Trading Arrangements, by Individual | |
Rule 10b5-1 Arrangement Adopted | false |
Non-Rule 10b5-1 Arrangement Adopted | false |
Rule 10b5-1 Arrangement Terminated | false |
Non-Rule 10b5-1 Arrangement Terminated | false |
Significant Accounting Polici_2
Significant Accounting Policies (Policies) | 6 Months Ended |
Dec. 30, 2023 | |
Accounting Policies [Abstract] | |
Fiscal Year | The Company’s reporting period is a 52/53 week fiscal year ending on the Saturday closest to June 30. The three month and six month periods ended December 30, 2023 and December 31, 2022, were both 13 week and 26 week periods. Fiscal year 2024 will end on June 29, 2024, which is a 52 week year. Fiscal year 2023 which ended on July 1, 2023, was also a 52 week year. Management’s Assessment of Liquidity Historically, we have financed operations and met our capital expenditure requirements primarily through cash flows provided by operations and borrowings under our credit facilities. We generated operating and net income of $3.9 million and $1.1 million respectively, during the 3-month period ended December 30, 2023, and have positive working capital of $193.9 million as of December 30, 2023. Due to the timing between the procurement of raw materials, production cycle and payment from our customers, we have relied on borrowings on our credit facilities and cash from operations to fund operations of the Company. Based on current projections, we anticipate generating cash from operations as revenue is expected to remain flat during the third quarter of fiscal year 2024 and decreasing working capital requirements as existing backlog is manufactured and shipped. As of December 30, 2023, approximately $14.4 million was available under the asset-based revolving credit facility with Bank of America, and an additional $2.0 million was available under the asset-based line of credit with Banorte Financial Group. We are also in discussions with multiple financial institutions to extend the borrowing capacity on our credit facility. If we are unable to meet projected operating results or extend our borrowing capacity, we may need to delay the purchase of raw materials or require our customers to fund inventory raw material costs ahead of production. Other options to increase our liquidity include factoring receivables or leveraging foreign owned assets for additional borrowing capacity. We believe that projected cash from operations, funds available under our asset-based revolving credit facility and additional financing options will be sufficient to meet our working and fixed capital requirements for at least the next 12 months. |
Reclassifications | Reclassifications |
Earnings Per Common Share | Earnings Per Common Share Basic earnings per common share (EPS) is computed by dividing net income (loss) by the weighted average number of common shares outstanding during the period. Diluted EPS is computed by dividing net income (loss) by the combination of other potentially dilutive weighted average common shares and the weighted average number of common shares outstanding during the period using the treasury stock method. The computation assumes the proceeds from the exercise of equity awards were used to repurchase common shares at the average market price during the period. The computation of diluted EPS does not assume conversion, exercise, or contingent issuance of common stock equivalent shares that would have an anti-dilutive effect on EPS. |
Derivative Instruments and Hedging Activities | Derivative Instruments and Hedging Activities The Company has entered into foreign currency forward contracts which are accounted for as cash flow hedges in accordance with ASC 815, Derivatives and Hedging. The effective portion of the gain or loss on the derivative is reported as a component of accumulated other comprehensive income (AOCI) and is reclassified into earnings in the same period in which the underlying hedged transaction affects earnings. The derivative’s effectiveness represents the change in fair value of the hedge that offsets the change in fair value of the hedged item. The Company uses derivatives to manage the variability of foreign currency fluctuations of expenses in our Mexico facilities. The foreign currency forward contracts have terms that are matched to the underlying transactions being hedged. As a result, these transactions fully offset the hedged risk and no ineffectiveness has been recorded. The Company’s foreign currency forward contracts potentially expose the Company to credit risk to the extent the counterparty may be unable to meet the terms of the agreement. The Company minimizes such risk by utilizing a counterparty with a strong credit rating. The Company’s counterparty to the foreign currency forward contracts is a major banking institution. This institution does not require collateral for the contracts, and the Company believes that the risk of the counterparty failing to meet their contractual obligations is remote. The Company does not enter into derivative instruments for trading or speculative purposes. |
Income Taxes | Income Taxes We compute our interim income tax provision through the use of an estimated annual effective tax rate (ETR) applied to year-to-date operating results and specific events that are discretely recognized as they occur. In determining the estimated annual ETR, we analyze various factors, including projections of our annual earnings, taxing jurisdictions in which the earnings will be generated, the impact of state and local income taxes, our ability to use tax credits and available tax planning alternatives. Discrete items, including the effect of changes in tax laws, tax rates, and certain circumstances with respect to valuation allowances or other unusual or non-recurring tax adjustments, are reflected in the period in which they occur as an addition to, or reduction from, the income tax provision, rather than included in the estimated annual ETR. Income taxes are accounted for under the asset and liability method. Deferred tax assets and liabilities are recognized for the estimated future tax consequences and benefits attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases, as well as tax credit and net operating loss carryforwards. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which temporary differences and carryforwards are expected to be recovered or settled. The effect on deferred tax assets and liabilities for a change in tax rates is recognized in the period that includes the enactment date. Valuation allowances are established when necessary to reduce deferred tax assets to the amount that is more likely than not to be realized. We utilize a two-step approach to recognizing and measuring uncertain tax positions. The first step is to evaluate the tax position for recognition by determining if the weight of available evidence indicates it is more likely than not that the position will be sustained on audit, including resolution of related appeals or litigation processes, if any. The second step is to measure the tax benefit as the largest amount which is more than 50% likely of being realized upon ultimate settlement. We consider many factors when evaluating and estimating our tax positions and tax benefits, which may require periodic adjustments based on new assessments and changes in estimates and which may not accurately forecast actual outcomes. Our policy is to recognize interest and penalties related to the underpayment of income taxes as a component of income tax expense. The tax years 2001 through the present remain open to examination by the major U.S. taxing jurisdictions to which we are subject. Refer to Note 5 for further discussions. |
Recently Issued Accounting Standards | Recently Issued Accounting Standards On Dec. 14, 2023, the Financial Accounting Standards Board (FASB) issued ASU 2023-09, Income Taxes (Topic 740): Improvements to Income Tax Disclosures. The ASU requires entities to disclose more detailed information relating to their reconciliation of statutory tax rate to effective tax rate, income taxes paid by jurisdiction, pretax income (or loss) from continuing operations, and income tax expense (or benefit). The ASU applies to the Company’s annual reporting period beginning in fiscal year 2026. The Company does not anticipate early adoption of the new disclosure standards. In September 2022, the Financial Accounting Standards Board issued Accounting Standards Update ("ASU") No. 2022-04, Liabilities—Supplier Finance Programs (Subtopic 405-50). This standard requires disclosure of the key terms of outstanding supplier finance programs and a roll forward of the related obligations. The new standard does not affect the recognition, measurement or financial statement presentation of supplier finance program obligations. The ASU became effective for the Company July 2, 2023, except for the roll forward requirement, which becomes effective July 2, 2024. This ASU, except for the roll forward requirement, was adopted retrospectively as of July 2, 2023 and did not have a material impact on our consolidated financial statements. In October 2021, the Financial Accounting Standards Board (FASB) issued Accounting Standards Update (ASU) 2021-08 amending Business Combination: (Topic 805), which was necessary due to 2014-09, Revenue from Contracts with Customers (Topic 606). The FASB issued this Update to improve the accounting for acquired revenue contracts with customers in a business combination by addressing diversity in practice and inconsistency related to (1) recognition of an acquired contract liability and (2) payment terms and their effect on subsequent revenue recognized by the acquirer. The Company adopted this amendment as of the effective date of July 2, 2023. These amendments are to be applied prospectively to business combinations occurring on or after the effective date of the amendments. The Company plans to apply the practical expedients as needed for any future acquisitions. The practical expedients cover contracts that were modified prior to acquisition date as well as determining which date an acquirer would have to determine the standalone selling price of each performance obligation in an acquired contract. This ASU did not have a material impact on our consolidated financial statements. In March of 2020, the FASB issued ASU 2020-03, Codification Improvements to Financial Instruments, which clarifies specific issues raised by stakeholders. Specifically, the ASU clarifies the following: 1) that all entities are required to provide the fair value option disclosures in ASC 825, Financial Instruments 2) clarifies that the portfolio exception in ASC 820, Fair Value Measurement, applies to nonfinancial items accounted for as derivatives under ASC 815, Derivatives and Hedging; 3) clarifies that for purposes of measuring expected credit losses on a net investment in a lease in accordance with ASC 326, Financial Instruments - Credit Losses, the lease term determined in accordance with ASC 842, Leases, should be used as the contractual term; 4) clarifies that when an entity regains control of financial assets sold, it should recognize an allowance for credit losses in accordance with ASC 326; and 5) aligns the disclosure requirements for debt securities in ASC 320, Investments - Debt Securities, with the corresponding requirements for depository and lending institutions in ASC 942, Financial Services - Depository and Lending. The amendments in the ASU have various effective dates and transition requirements which are dependent on timing of adoption of ASU 2016-13. The Company adopted this amendment as of the effective date of July 2, 2023. This ASU did not have a material impact on our consolidated financial statements. In June 2016, the FASB issued ASU 2016-13 “Financial Instruments - Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments” and also issued subsequent amendments to the initial guidance: ASU 2018-19, ASU 2019-04 and ASU 2019-05, which replaces the existing incurred loss impairment model with an expected credit loss model and requires a financial asset measured at amortized cost to be presented at the net amount expected to be collected. The guidance is effective for the Company beginning in the first quarter of fiscal year 2024 with early adoption permitted. The Company adopted this amendment as of the effective date of July 2, 2023. This ASU did not have a material impact on our consolidated financial statements. |
Long-Term Debt (Tables)
Long-Term Debt (Tables) | 6 Months Ended |
Dec. 30, 2023 | |
Debt Disclosure [Abstract] | |
Schedule of Maturities of Long-term Debt | Debt maturities as of December 30, 2023 for the next five years and thereafter are as follows (in thousands): Fiscal Years Ending Amount 2024 (1) $ 1,520 2025 3,123 2026 2,081 2027 110,468 2028 1,032 2029 - Thereafter 816 Total debt $ 119,040 Unamortized debt issuance costs (1,078) Long-term debt, net of debt issuance costs $ 117,962 (1) Represents scheduled payments for the remaining six-month period ending June 29, 2024. |
Earnings Per Share (Tables)
Earnings Per Share (Tables) | 6 Months Ended |
Dec. 30, 2023 | |
Earnings Per Share [Abstract] | |
Schedule of Antidilutive Securities and Outstanding Equity Awards | These antidilutive securities occur when equity awards outstanding have an option price greater than the average market price for the period. Three Months Ended (in thousands, except share and per share information) December 30, 2023 December 31, 2022 Net income $ 1,084 $ 967 Weighted average shares outstanding—basic 10,762 10,762 Effect of dilutive common stock awards 127 70 Weighted average shares outstanding—diluted 10,889 10,832 Net income per share—basic $ 0.10 $ 0.09 Net income per share—diluted $ 0.10 $ 0.09 Antidilutive SARs not included in diluted earnings per share 525 904 Six Months Ended (in thousands, except per share information) December 30, 2023 December 31, 2022 Net income $ 1,419 $ 2,119 Weighted average shares outstanding—basic 10,762 10,762 Effect of dilutive common stock awards 127 70 Weighted average shares outstanding—diluted 10,889 10,832 Net income per share—basic $ 0.13 $ 0.20 Net income per share—diluted $ 0.13 $ 0.20 Antidilutive SARs not included in diluted earnings per share 525 904 |
Share-based Compensation (Table
Share-based Compensation (Tables) | 6 Months Ended |
Dec. 30, 2023 | |
Share-Based Payment Arrangement [Abstract] | |
Schedule of Share-based Compensation for the Awards Granted | The grant date fair value for the awards granted below were estimated using the Black Scholes option valuation method: July 29, 2022 SARs Granted 145,000 Strike Price $ 5.10 Fair Value $ 2.09 |
Derivative Financial Instrume_2
Derivative Financial Instruments (Tables) | 6 Months Ended |
Dec. 30, 2023 | |
Derivative Instruments and Hedging Activities Disclosure [Abstract] | |
Schedule of Derivative Instruments | As of December 30, 2023, the aggregate notional amount of the Company’s outstanding foreign currency contracts along with their unrealized gain (losses) are expected to mature as summarized below (in thousands): Quarter Ending Notional Contracts in MXN Notional Contracts in USD Estimated Fair Value March 30, 2024 $ 61,775 $ 3,369 $ 247 |
Schedule of Gain (Loss) of Derivative Instruments in Statement of Operations | The following tables summarize the gain (loss) on derivative instruments, net of tax, on the Consolidated Statements of Income for the three months ended December 30, 2023 and December 31, 2022, respectively (in thousands): Derivatives Designated as Hedging Instruments Classification of Gain (Loss) Reclassified from Accumulated OCI into Income (Effective Portion) AOCI Balance Effective Effective Portion AOCI Balance Forward contracts Cost of sales $ — $ 263 $ (72) $ 191 Interest rate swap Interest expense (39) — 39 — Total $ (39) $ 263 $ (33) $ 191 Derivatives Designated as Hedging Instruments Classification of Gain (Loss) Reclassified from Accumulated OCI into Income (Effective Portion) AOCI Balance Effective Effective Portion AOCI Balance Forward contracts Cost of sales $ — $ — $ — $ — Interest rate swap Interest expense (272) — 59 (213) Total $ (272) $ — $ 59 $ (213) The following tables summarize the gain (loss) on derivative instruments, net of tax, on the Consolidated Statements of Income for the six months ended December 30, 2023 and December 31, 2022, respectively (in thousands): Derivatives Designated as Hedging Instruments Classification of Gain (Loss) Reclassified from Accumulated OCI into Income (Effective Portion) AOCI Balance Effective Effective Portion AOCI Balance Forward contracts Cost of sales $ — $ 263 $ (72) $ 191 Interest rate swap Interest expense (97) — 97 — Total $ (97) $ 263 $ 25 $ 191 Derivatives Designated as Hedging Instruments Classification of Gain (Loss) Reclassified from Accumulated OCI into Income (Effective Portion) AOCI Balance Effective Effective Portion AOCI Balance Forward contracts Cost of sales $ (79) $ — $ 79 $ — Interest rate swap Interest expense (346) — 133 (213) Total $ (425) $ — $ 212 $ (213) |
Revenue (Tables)
Revenue (Tables) | 6 Months Ended |
Dec. 30, 2023 | |
Revenue from Contract with Customer [Abstract] | |
Schedule of Contract Assets | The following table summarizes the activity in the Company’s contract assets during the six months ended December 30, 2023 (in thousands): Contract Assets Beginning balance, July 1, 2023 29,925 Revenue recognized 254,185 Amounts collected or invoiced (256,340) Ending balance, December 30, 2023 $ 27,770 |
Schedule of Disaggregation of Revenue | The following table presents the Company’s revenue disaggregated for the three and six months ended December 30, 2023 and December 31, 2022 (in thousands): Revenue Recognition Three Months Ended Six Months Ended December 30, 2023 December 31, 2022 December 30, 2023 December 31, 2022 Over-Time $ 124,205 $ 119,649 $ 254,185 $ 254,207 Point-in-Time 21,212 4,059 38,995 6,764 Total $ 145,417 $ 123,708 $ 293,180 $ 260,971 |
Leases (Tables)
Leases (Tables) | 6 Months Ended |
Dec. 30, 2023 | |
Leases [Abstract] | |
Schedule of Lease Cost | The components of lease cost for the three months and six months ended December 30, 2023 and were (in thousands): Three Months Ended Six Months Ended December 30, 2023 December 31, 2022 December 30, 2023 December 31, 2022 Lease cost Classification Operating lease cost Cost of sales $ 1,223 $ 2,441 $ 2,350 $ 3,775 Operating lease cost Selling, general and administrative expenses $ 183 $ 367 $ 367 $ 551 Financing lease cost Cost of sales $ 1,186 $ 1,859 $ 2,465 $ 2,759 Financing lease cost Selling, general and administrative expenses $ 49 $ 77 $ 104 $ 115 Total lease cost $ 2,641 $ 4,744 $ 5,286 $ 7,200 Fixed lease cost $ 1,336 $ 4,435 $ 2,434 $ 6,656 Short-term lease cost $ 1,305 $ 309 $ 2,852 $ 544 Total lease cost $ 2,641 $ 4,744 $ 5,286 $ 7,200 |
Schedule of Lease Assets and Liabilities | Amounts reported in the Consolidated Balance Sheet as of December 30, 2023 were (in thousands, except weighted average lease term and discount rate): December 30, 2023 July 1, 2023 Operating Leases: Operating lease right of use assets $ 18,104 $ 16,202 Operating lease liabilities (1) $ 18,104 $ 16,202 Weighted-average remaining lease term (in years) Operating leases 4.44 4.55 Weighted-average discount rate Operating leases 4.28% 4.00% Financing Leases (2) : Financing lease right of use assets $ 4,610 $ 9,718 Financing lease liabilities $ 3,170 $ 8,278 Weighted-average remaining lease term (in years) Financing leases 1.23 1.89 Weighted-average discount rate Financing leases 10.88% 9.96% (1) The current portion of the total operating lease liabilities of $5.7 million is classified under Other Current Liabilities , resulting in $12.4 million classified under Operating Lease Liabilities in the Long-term Liabilities section of the condensed consolidated balance sheet. (2) The total finance lease right of use assets of $4.6 million is classified under Other Long-term Assets The current portion of the total finance lease liabilities of $2.5 million is classified under Current portion of debt, net resulting in $0.6 million classified in Other Long-term Liabilities section of the condensed consolidated balance sheet. |
Schedule of Maturities of Operating Leases Liability | Future lease payments under non-cancellable leases as of December 30, 2023 are as follows (in thousands): Fiscal Years Ending Operating Leases Finance Leases 2024 (1) $ 3,034 $ 1,112 2025 5,080 1,909 2026 4,147 501 2027 3,238 — 2028 2,281 — Thereafter 1,873 — Total undiscounted lease payments 19,653 3,522 Less: present value discount (1,549) (352) Total lease liabilities $ 18,104 $ 3,170 |
Schedule of Maturities of Finance Leases Liability | Future lease payments under non-cancellable leases as of December 30, 2023 are as follows (in thousands): Fiscal Years Ending Operating Leases Finance Leases 2024 (1) $ 3,034 $ 1,112 2025 5,080 1,909 2026 4,147 501 2027 3,238 — 2028 2,281 — Thereafter 1,873 — Total undiscounted lease payments 19,653 3,522 Less: present value discount (1,549) (352) Total lease liabilities $ 18,104 $ 3,170 |
Basis of Presentation (Details)
Basis of Presentation (Details) - USD ($) $ in Thousands | 3 Months Ended | 6 Months Ended | |||
Dec. 30, 2023 | Dec. 31, 2022 | Dec. 30, 2023 | Dec. 31, 2022 | Jul. 01, 2023 | |
Debt Instrument [Line Items] | |||||
Operating income | $ 3,948 | $ 3,608 | $ 7,216 | $ 6,969 | |
Net income | 1,084 | $ 967 | 1,419 | $ 2,119 | |
Working capital | 193,900 | 193,900 | |||
Line of credit available under asset-based revolving credit facility | 14,400 | 14,400 | $ 4,600 | ||
Banorte Financial Group | |||||
Debt Instrument [Line Items] | |||||
Line of credit available under asset-based revolving credit facility | $ 2,000 | $ 2,000 |
Inventories - Narrative (Detail
Inventories - Narrative (Details) - USD ($) $ in Thousands | Dec. 30, 2023 | Jul. 01, 2023 |
Inventory Disclosure [Abstract] | ||
Inventories | $ 124,054 | $ 137,911 |
Long-Term Debt - Narrative (Det
Long-Term Debt - Narrative (Details) - USD ($) | 6 Months Ended | |||||||
Dec. 11, 2023 | Aug. 26, 2022 | Nov. 24, 2020 | Dec. 30, 2023 | Sep. 19, 2023 | Jul. 01, 2023 | Sep. 03, 2021 | Aug. 14, 2020 | |
Debt Disclosure [Line Items] | ||||||||
Revolving credit facility outstanding amount | $ 105,600,000 | $ 115,400,000 | ||||||
Increase in revolving line of credit | $ 120,000,000 | |||||||
Letters of credit outstanding amount | 300,000 | 300,000 | ||||||
Additional availability of line of credit | 14,400,000 | $ 4,600,000 | ||||||
Long-term debt | 117,962,000 | |||||||
Interest rate on outstanding debt | 5.52% | 4.85% | ||||||
Banorte Financial Group | ||||||||
Debt Disclosure [Line Items] | ||||||||
Long-term debt, term | 3 years | |||||||
Revolving credit facility outstanding amount | $ 5,900,000 | 3,900,000 | ||||||
Additional availability of line of credit | 2,000,000 | |||||||
Americ Bank Equipment Financing Arrangement | ||||||||
Debt Disclosure [Line Items] | ||||||||
Long-term debt | 4,900,000 | |||||||
Debt instrument, face amount | $ 5,500,000 | |||||||
Periodic payment of principal amount | $ 94,000 | |||||||
Minimum | ||||||||
Debt Disclosure [Line Items] | ||||||||
Interest rate on outstanding debt | 4.85% | 4.85% | ||||||
Minimum | Americ Bank Equipment Financing Arrangement | ||||||||
Debt Disclosure [Line Items] | ||||||||
Interest rate (as percent) | 6% | |||||||
Maximum | ||||||||
Debt Disclosure [Line Items] | ||||||||
Interest rate on outstanding debt | 14.25% | 8.22% | ||||||
Maximum | Americ Bank Equipment Financing Arrangement | ||||||||
Debt Disclosure [Line Items] | ||||||||
Interest rate (as percent) | 8% | |||||||
Line of Credit | Banorte Financial Group | ||||||||
Debt Disclosure [Line Items] | ||||||||
Variable rate on line of credit facility (percent) | 2.75% | |||||||
Line of Credit | LIBOR | ||||||||
Debt Disclosure [Line Items] | ||||||||
Variable rate on line of credit facility (percent) | 1% | |||||||
Percentage on variable floor rate (as percent) | 0.50% | |||||||
Line of Credit | Fixed Rate | ||||||||
Debt Disclosure [Line Items] | ||||||||
Variable rate on line of credit facility (percent) | 2.50% | |||||||
Equipment Term Loan | ||||||||
Debt Disclosure [Line Items] | ||||||||
Long-term debt | $ 1,800,000 | $ 1,100,000 | $ 2,300,000 | $ 5,000,000 | ||||
Periodic payment of principal amount | 94,000 | |||||||
JZ Equipment Term Loan | ||||||||
Debt Disclosure [Line Items] | ||||||||
Long-term debt | $ 6,000,000 | $ 2,800,000 | $ 3,400,000 | |||||
Periodic payment of principal amount | $ 100,000 | |||||||
Wells Fargo Bank | ||||||||
Debt Disclosure [Line Items] | ||||||||
Long-term debt, term | 5 years | |||||||
Revolving credit facility outstanding amount | $ 93,000,000 | |||||||
Bank Of America | ||||||||
Debt Disclosure [Line Items] | ||||||||
Increase in interest rate | 0.25% | |||||||
Bank Of America | Line of Credit | ||||||||
Debt Disclosure [Line Items] | ||||||||
Percentage of additional interest rate on default | 2% | |||||||
Percentage of unused portion of credit | 0.25% | |||||||
Bank Of America | Line of Credit | LIBOR | Minimum | ||||||||
Debt Disclosure [Line Items] | ||||||||
Interest rate (as percent) | 2.25% | |||||||
Bank Of America | Line of Credit | LIBOR | Maximum | ||||||||
Debt Disclosure [Line Items] | ||||||||
Interest rate (as percent) | 2.75% | |||||||
Bank Of America | Line of Credit | Base Rate | Minimum | ||||||||
Debt Disclosure [Line Items] | ||||||||
Variable rate on line of credit facility (percent) | 1.25% | |||||||
Bank Of America | Line of Credit | Base Rate | Maximum | ||||||||
Debt Disclosure [Line Items] | ||||||||
Variable rate on line of credit facility (percent) | 1.75% | |||||||
Revolving credit facility | Line of Credit | Fed Funds Effective Rate Overnight Index Swap Rate | ||||||||
Debt Disclosure [Line Items] | ||||||||
Variable rate on line of credit facility (percent) | 0.50% |
Long-Term Debt - Schedule of Ma
Long-Term Debt - Schedule of Maturities of Long-term Debt (Details) $ in Thousands | Dec. 30, 2023 USD ($) |
Debt Disclosure [Abstract] | |
2024 | $ 1,520 |
2025 | 3,123 |
2026 | 2,081 |
2027 | 110,468 |
2028 | 1,032 |
2029 - Thereafter | 816 |
Total debt | 119,040 |
Unamortized debt issuance costs | (1,078) |
Long-term debt, net of debt issuance costs | $ 117,962 |
Income Taxes - Narrative (Detai
Income Taxes - Narrative (Details) $ in Millions | 6 Months Ended |
Dec. 30, 2023 USD ($) | |
Income Tax Disclosure [Abstract] | |
Foreign tax credits related to future repatriations of earnings | $ 7.8 |
Estimated federal and state income taxes and potential withholding taxes | 0.8 |
Gross potential research and development (R&D) tax credit | 10 |
Unrecognized tax benefits associated with federal tax credits | 3.1 |
Deferred tax benefit | $ 6.9 |
Earnings Per Share - Schedule o
Earnings Per Share - Schedule of Antidilutive Securities and Outstanding Equity Awards (Details) - USD ($) $ / shares in Units, shares in Thousands, $ in Thousands | 3 Months Ended | 6 Months Ended | ||
Dec. 30, 2023 | Dec. 31, 2022 | Dec. 30, 2023 | Dec. 31, 2022 | |
Earnings Per Share [Abstract] | ||||
Net income | $ 1,084 | $ 967 | $ 1,419 | $ 2,119 |
Weighted average shares outstanding — basic (in shares) | 10,762 | 10,762 | 10,762 | 10,762 |
Effect of dilutive common stock awards (in shares) | 127 | 70 | 127 | 70 |
Weighted average shares outstanding—diluted (in shares) | 10,889 | 10,832 | 10,889 | 10,832 |
Net income per share—basic (in USD per share) | $ 0.10 | $ 0.09 | $ 0.13 | $ 0.20 |
Net income per share—diluted (in USD per share) | $ 0.10 | $ 0.09 | $ 0.13 | $ 0.20 |
Antidilutive SARs not included in diluted earnings per share (in shares) | 525 | 904 | 525 | 904 |
Share-based Compensation - Narr
Share-based Compensation - Narrative (Details) - USD ($) | 3 Months Ended | 6 Months Ended | ||
Dec. 30, 2023 | Dec. 31, 2022 | Dec. 30, 2023 | Dec. 31, 2022 | |
Share-based Compensation Arrangement by Share-based Payment Award [Line Items] | ||||
Share-based compensation arrangement vesting period (in year) | 3 years | |||
Share-based compensation arrangement expiration period (in year) | 5 years | |||
Unrecognized unvested share-based compensation arrangements | $ 200,000 | $ 200,000 | ||
Weighted average period (in years) | 1 year 6 months | |||
Stock Appreciation Rights (SARs) | ||||
Share-based Compensation Arrangement by Share-based Payment Award [Line Items] | ||||
Total share-based compensation expense | $ 52,297 | $ 62,000 | $ 111,239 | $ 102,000 |
Share-based Compensation - Sche
Share-based Compensation - Schedule of Share-based Compensation for the Awards Granted (Details) - Stock Appreciation Rights (SARs) shares in Thousands | Jul. 29, 2022 $ / shares shares |
Share-based Compensation Arrangement by Share-based Payment Award [Line Items] | |
SARs Granted (in dollars per share) | shares | 145 |
Strike Price (in dollars per share) | $ 5.10 |
Fair Value | $ 2.09 |
Commitments and Contingencies -
Commitments and Contingencies - Narrative (Details) - USD ($) | 3 Months Ended | 6 Months Ended | |||
Dec. 30, 2023 | Dec. 31, 2022 | Dec. 30, 2023 | Dec. 31, 2022 | Jul. 01, 2023 | |
Commitments and Contingencies Disclosure [Abstract] | |||||
Amount of warranty reserve | $ 107,000 | $ 107,000 | $ 29,000 | ||
Gain on insurance proceeds, net of losses | $ 0 | $ 2,710,000 | $ 431,000 | $ 3,644,000 |
Derivative Financial Instrume_3
Derivative Financial Instruments - Narrative (Details) $ in Thousands | 3 Months Ended | 6 Months Ended | ||
Dec. 30, 2023 USD ($) | Dec. 30, 2023 USD ($) | Dec. 30, 2023 MXN ($) | Aug. 14, 2020 USD ($) | |
Derivative [Line Items] | ||||
Derivative, notional amount | $ 776,500 | |||
Net amount of unrealized gain expected to be reclassified | $ 200,000 | $ 200,000 | ||
Equipment Term Loan | ||||
Derivative [Line Items] | ||||
Derivative, notional amount | $ 148,400 | |||
Foreign Exchange Contract | ||||
Derivative [Line Items] | ||||
Derivative, notional amount | 3,369,000 | 3,369,000 | $ 61,775 | |
Foreign currency forward contracts entered | 6,500,000 | 6,500,000 | ||
Foreign currency forward contracts settled | $ 3,200,000 | $ 3,200,000 |
Derivative Financial Instrume_4
Derivative Financial Instruments - Schedule of Derivative Instruments (Details) $ in Thousands | Dec. 30, 2023 MXN ($) | Dec. 30, 2023 USD ($) | Aug. 14, 2020 USD ($) |
Derivative [Line Items] | |||
Derivative, notional amount | $ 776,500 | ||
Foreign Exchange Contract | |||
Derivative [Line Items] | |||
Derivative, notional amount | $ 61,775 | $ 3,369,000 | |
Estimated Fair Value | $ 247,000 |
Derivative Financial Instrume_5
Derivative Financial Instruments - Schedule of Gain (Loss) of Derivative Instruments in Statement of Operations (Details) - USD ($) $ in Thousands | 3 Months Ended | 6 Months Ended | ||
Dec. 30, 2023 | Dec. 31, 2022 | Dec. 30, 2023 | Dec. 31, 2022 | |
Derivatives used in Net Investment Hedge, Net of Tax [Roll Forward] | ||||
Accumulated Other Comprehensive Income, Beginning balance | $ (97) | |||
Accumulated Other Comprehensive Income, Ending balance | $ 191 | 191 | ||
Designated As Hedging Instrument | ||||
Derivatives used in Net Investment Hedge, Net of Tax [Roll Forward] | ||||
Accumulated Other Comprehensive Income, Beginning balance | (39) | $ (272) | (97) | $ (425) |
Effective Portion Recorded In AOCI | 263 | 0 | 263 | 0 |
Effective Portion Reclassified From AOCI Into Income | (33) | 59 | 25 | 212 |
Accumulated Other Comprehensive Income, Ending balance | 191 | (213) | 191 | (213) |
Forward contracts | Designated As Hedging Instrument | ||||
Derivatives used in Net Investment Hedge, Net of Tax [Roll Forward] | ||||
Accumulated Other Comprehensive Income, Beginning balance | 0 | 0 | 0 | (79) |
Effective Portion Recorded In AOCI | 263 | 0 | 263 | 0 |
Effective Portion Reclassified From AOCI Into Income | (72) | 0 | (72) | 79 |
Accumulated Other Comprehensive Income, Ending balance | 191 | 0 | 191 | 0 |
Interest rate swap | Designated As Hedging Instrument | ||||
Derivatives used in Net Investment Hedge, Net of Tax [Roll Forward] | ||||
Accumulated Other Comprehensive Income, Beginning balance | (39) | (272) | (97) | (346) |
Effective Portion Recorded In AOCI | 0 | 0 | 0 | 0 |
Effective Portion Reclassified From AOCI Into Income | 39 | 59 | 97 | 133 |
Accumulated Other Comprehensive Income, Ending balance | $ 0 | $ (213) | $ 0 | $ (213) |
Revenue - Schedule of Contract
Revenue - Schedule of Contract Assets (Details) $ in Thousands | 6 Months Ended |
Dec. 30, 2023 USD ($) | |
Contract with Customer, Asset, Allowance for Credit Loss [Roll Forward] | |
Beginning balance | $ 29,925 |
Revenue recognized | 254,185 |
Amounts collected or invoiced | (256,340) |
Ending balance | $ 27,770 |
Revenue - Schedule of Disaggreg
Revenue - Schedule of Disaggregation of Revenue (Details) - USD ($) $ in Thousands | 3 Months Ended | 6 Months Ended | ||
Dec. 30, 2023 | Dec. 31, 2022 | Dec. 30, 2023 | Dec. 31, 2022 | |
Disaggregation of Revenue [Line Items] | ||||
Net sales | $ 145,417 | $ 123,708 | $ 293,180 | $ 260,971 |
Over-Time | ||||
Disaggregation of Revenue [Line Items] | ||||
Net sales | 124,205 | 119,649 | 254,185 | 254,207 |
Point-in-Time | ||||
Disaggregation of Revenue [Line Items] | ||||
Net sales | $ 21,212 | $ 4,059 | $ 38,995 | $ 6,764 |
Leases - Narrative (Details)
Leases - Narrative (Details) | Dec. 30, 2023 |
Lessee, Lease, Description [Line Items] | |
Operating lease, discount rate (as percent) | 4.28% |
Minimum | |
Lessee, Lease, Description [Line Items] | |
Operating lease, term (in years) | 1 year |
Maximum | |
Lessee, Lease, Description [Line Items] | |
Operating lease, term (in years) | 10 years |
Leases - Schedule of Lease Cost
Leases - Schedule of Lease Cost (Details) - USD ($) $ in Thousands | 3 Months Ended | 6 Months Ended | ||
Dec. 30, 2023 | Dec. 31, 2022 | Dec. 30, 2023 | Dec. 31, 2022 | |
Lessee, Lease, Description [Line Items] | ||||
Total lease cost | $ 2,641 | $ 4,744 | $ 5,286 | $ 7,200 |
Fixed lease cost | 1,336 | 4,435 | 2,434 | 6,656 |
Short-term lease cost | 1,305 | 309 | 2,852 | 544 |
Cost of sales | ||||
Lessee, Lease, Description [Line Items] | ||||
Operating lease cost | 1,223 | 2,441 | 2,350 | 3,775 |
Financing lease cost | 1,186 | 1,859 | 2,465 | 2,759 |
Selling, general and administrative expenses | ||||
Lessee, Lease, Description [Line Items] | ||||
Operating lease cost | 183 | 367 | 367 | 551 |
Financing lease cost | $ 49 | $ 77 | $ 104 | $ 115 |
Leases - Schedule of Lease Asse
Leases - Schedule of Lease Assets and Liabilities (Details) - USD ($) $ in Thousands | Dec. 30, 2023 | Jul. 01, 2023 |
Operating Leases: | ||
Operating lease right-of-use assets, net | $ 18,104 | $ 16,202 |
Operating lease liabilities | $ 18,104 | $ 16,202 |
Weighted-average remaining lease term (in years) | ||
Operating leases | 4 years 5 months 8 days | 4 years 6 months 18 days |
Weighted-average discount rate | ||
Operating leases (as percent) | 4.28% | 4% |
Financing Leases: | ||
Financing lease right of use assets | $ 4,610 | $ 9,718 |
Financing lease liabilities | $ 3,170 | $ 8,278 |
Weighted-average remaining lease term (in years) | ||
Financing leases | 1 year 2 months 23 days | 1 year 10 months 20 days |
Weighted-average discount rate | ||
Financing leases (as percent) | 10.88% | 9.96% |
Operating lease liability, current | $ 5,700 | |
Operating Lease, Liability, Statement of Financial Position [Extensible Enumeration] | Other Liabilities | |
Operating lease liabilities | $ 12,380 | $ 10,317 |
Operating Lease, Liability, Noncurrent, Statement of Financial Position [Extensible Enumeration] | Operating lease liabilities | |
Finance Lease, Right-of-Use Asset, Statement of Financial Position [Extensible Enumeration] | Other | |
Finance Lease, Liability, Current, Statement of Financial Position [Extensible Enumeration] | Current portion of debt, net | |
Noncurrent finance liability | $ 600 | |
Finance Lease, Liability, Noncurrent, Statement of Financial Position [Extensible Enumeration] | Other long-term obligations | |
Current portion of Debt | ||
Weighted-average discount rate | ||
Current finance lease liability | $ 2,500 |
Leases - Schedule of Maturities
Leases - Schedule of Maturities of Future Lease Payment (Details) - USD ($) $ in Thousands | Dec. 30, 2023 | Jul. 01, 2023 |
Operating Leases | ||
2024 | $ 3,034 | |
2025 | 5,080 | |
2026 | 4,147 | |
2027 | 3,238 | |
2028 | 2,281 | |
Thereafter | 1,873 | |
Total undiscounted lease payments | 19,653 | |
Less: present value discount | (1,549) | |
Total operating lease liabilities | 18,104 | $ 16,202 |
Finance Leases | ||
2024 | 1,112 | |
2025 | 1,909 | |
2026 | 501 | |
2027 | 0 | |
2028 | 0 | |
Thereafter | 0 | |
Total undiscounted lease payments | 3,522 | |
Less: present value discount | (352) | |
Financing lease liabilities | $ 3,170 | $ 8,278 |